Table 4

Main findings (secondary outcomes).

Angina

Heart failure

Diabetes incidence


Diuretics vs. BB

0.96 (0.28 to 5.78)

0.73 (0.54 to 0.96)

1.09 (0.80 to 1.44)


⊕ OOO

⊕ ⊕ ⊕ O

⊕ ⊕ OO


Diuretics vs. ACE

0.97 (0.42 to 2.51)

0.88 (0.76 to 1.06)

1.43 (1.12 to 1.83)


⊕ ⊕ OO

⊕ ⊕ OO

⊕ ⊕ ⊕ O


Diuretics vs. CCB

1.05 (0.56 to 2.19)

0.73 (0.62 to 0.84)

1.27 (1.05 to 1.57)


⊕ ⊕ OO

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ ⊕


Diuretics vs. alpha-blockers

0.89 (0.31 to 2.52)

0.51 (0.40 to 0.64)

-


⊕ OOO

⊕ ⊕ ⊕ O


Diuretics vs. ARB

0.86 (0.39 to 3.27)

0.80 (0.61 to 0.98)

1.59 (1.23 to 2.12)


⊕ OOO

⊕ ⊕ OO

⊕ ⊕ OO


BB vs. ACE

1.03 (0.17 to 3.76)

1.21 (0.91 to 1.69)

1.31 (0.95 to 1.88)


⊕ OOO

⊕ OOO

⊕ OOO


BB vs. CCB

1.10 (0.23 to 3.31)

1.00 (0.76 to 1.33)

1.17 (0.89 to 1.61)


⊕ OOO

⊕ OOO

⊕ OOO


BB vs. alpha-blockers

0.93 (0.11 to 4.35)

0.69 (0.50 to 1.02)

-


⊕ OOO

⊕ OOO


BB vs. ARB

0.88 (0.31 to 2.58)

1.08 (0.86 to 1.38)

1.46 (1.15 to 1.98)


⊕ ⊕ OO

⊕ ⊕ ⊕ ⊕

⊕ ⊕ ⊕ ⊕


ACE vs. CCB

1.08 (0.48 to 2.44)

0.82 (0.69 to 0.94)

0.89 (0.73 to 1.10)


⊕ OOO

⊕ ⊕ ⊕ O

⊕ ⊕ OO


ACE vs. alpha-blockers

0.91 (0.22 to 3.42)

0.58 (0.43 to 0.75)

-


⊕ OOO

⊕ ⊕ OO


ACE vs. ARB

0.86 (0.35 to 3.50)

0.90 (0.67 to 1.10)

1.11 (0.85 to 1.51)


⊕ OOO

⊕ OOO

⊕ OOO


CCB vs. alpha-blockers

0.85 (0.23 to 2.78)

0.70 (0.53 to 0.92)

-


⊕ OOO

⊕ ⊕ OO


CCB vs. ARB

0.81 (0.45 to 2.30)

1.10 (0.87 to 1.31)

1.25 (1.02 to 1.56)


⊕ ⊕ OO

⊕ ⊕ ⊕ O

⊕ ⊕ ⊕ ⊕


Alpha-blockers vs. ARB

0.95 (0.29 to 5.71)

1.57 (1.09 to 2.12)

-


⊕ OOO

⊕ ⊕ OO


ACE, Angiotensin Converting Enzyme Inhibitors; ARB, Angiotensin Receptor Blockers; BB, Beta-blockers; CCB, Calcium Channel Blockers; ⊕ ⊕ ⊕ ⊕, High quality evidence; ⊕ ⊕ ⊕ O, Moderate quality evidence; ⊕ ⊕ OO, Low quality evidence; ⊕ OOO, Very low quality evidence

Fretheim et al. BMC Medicine 2012 10:33   doi:10.1186/1741-7015-10-33

Open Data